OXiGENE is highly committed to delivering value to its shareholders. With a pipeline of high-potential therapeutic candidates that have demonstrated promising results to date in clinical trials, and a highly experienced management team, we're working to translate innovative science into important, next-generation therapeutic products that deliver significant medical benefits to patients suffering from cancer and eye disease.

OXiGENE is listed on the Nasdaq Global Market and the Stockholm Stock Exchange under the symbol "OXGN."

OXiGENE is headquartered in Waltham, Massachusetts and maintains drug development operations in South San Francisco, California.

[02.04.10] OXiGENE Announces Results of Stockholder Vote on Proposed Merger With VaxGen

[12.07.09] OXiGENE Reports Promising Preclinical Data Using OXi4503 in Acute Myelogenous Leukemia Models at ASH Conference

View all releases »